Pfizer (PFE) Secures $1.5 Billion For Berobenatide Development Sasha Jovanovic Fri, November 13, 2026 at 7:19 PM EST 3 min read PFE +0.34% GC=F +0.06% Trade Pfizer on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Pfizer (NYSE:PFE) announced a partnership with Blackstone Life Sciences to co-fund late stage development of berobenatide, its GLP-1 obesity drug candidate.
The arrangement provides up to $1.5b in development funding for berobenatide, focused on chronic weight management and obesity related conditions.
Pfizer keeps full operational control of berobenatide, while Blackstone Life Sciences receives milestone based economics linked to the program's progress.
This berobenatide funding deal with Blackstone Life Sciences is worth weighing alongside the rest of our Pfizer findings. We have also flagged 4 warning signs for Pfizer.
Obesity treatments are drawing significant capital flows, so it can help to compare Pfizer's move with other businesses in related themes via 33 elite gold producer stocks.
Pfizer is a large US-based pharmaceuticals group that discovers, develops, manufactures and sells biopharmaceutical products worldwide, so this berobenatide project fits into an established global research and commercial footprint. The obesity focus positions the business within one of the more heavily funded treatment areas in drug development today.
2 things going right for Pfizer that this headline doesn't cover.
The investment story around Pfizer leans on obesity and oncology turning into large non COVID pillars, while a big cost saving plan protects profitability. This berobenatide co funding deal goes right at that Narrative because it changes how the obesity build out is financed and executed.
"Development of Pfizer's obesity and metabolic disease franchise, led by berobenatide with Phase IIb and extension data that management is using to target a first obesity approval in 2028 within a market it estimates could reach US$120b to US$150b by 2030, reinforces the idea that a new long term revenue pillar is being built into future earnings expectations..."
See how the full story points towards a $29.72 fair value for Pfizer.
This agreement directly supports the obesity catalyst in the Narrative. Pfizer keeps full ownership and operational control of berobenatide, while shifting up to US$1.5b of development spend to Blackstone. That structure can help the business keep R&D intensity high on obesity and oncology without stretching the cost base that the US$9.7b savings plan is meant to slim down.
The same deal also puts pressure on the risk side that analysts already flag. A larger, multi trial obesity program increases exposure to pipeline setbacks, especially against competitors such as Eli Lilly and Novo Nordisk that are already entrenched in GLP 1 therapies. If trial timelines slip or data underwhelm, Pfizer would still face the heavier investment load and the legal and debt risks that are already on the checklist.
Whether this Blackstone partnership looks attractive or not depends on which Pfizer Narrative you lean on: cost disciplined obesity expansion, or concern that a bigger bet magnifies existing pipeline and balance sheet risks.
Headline figures only tell part of the story, and recent checks suggest something in Pfizer's reported profits and accounting mix deserves a closer look before you rely on the top line result. See what our checks flag about the quality of Pfizer's earnings.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
